HZNP News and Press, Horizon Therapeutics Public Limited Company From 05/02/22

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G...

HQL pays regular quarterly dividends with a close to double digit yield, and despite poor price growth over medium and long run, HQL’s total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movemen...

Horizon Ranked in Top Five for Patient Centricity, Patient-Group Relations and High Integrity Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked fifth in overall corporate reputation among patient groups that have worked directly with the company and ...

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure thr...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve. The Horizon Prize poses a unique question to encourage entrepreneurs and innovators worldwide to think creatively to solve a ...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2022 financial results on Wednesday, May 4, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financi...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and a big biotech trade. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping ...

An analysis of a phase 3 trial found that Horizon Therapeutics' (NASDAQ:HZNP) neuromyelitis optica spectrum disorder treatment Uplizna (inebilizymab) is effective for treating patients after one attack. Results showed among those with one attack prior to study initiation, 4.2% treated with Up...

-- Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UP...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...